It Seems Galectin Therapeutics Inc (NASDAQ:GALT) Will Go Down. Just Reported More Shorted Shares

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment increased to 2.15 in 2019 Q1. Its up 1.09, from 1.06 in 2018Q4. It increased, as 3 investors sold Galectin Therapeutics, Inc. shares while 10 reduced holdings. 17 funds opened positions while 11 raised stakes. 6.26 million shares or 31.05% more from 4.77 million shares in 2018Q4 were reported.
Moreover, Bluecrest Capital Mgmt has 0.01% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 45,280 shares. Pnc Finance Ser Inc accumulated 47,164 shares. Stratos Wealth Ptnrs Ltd reported 40,950 shares. Verition Fund Management Ltd Com owns 14,808 shares for 0% of their portfolio. Laurion Management Lp invested 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). State Street has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 98,403 shares. 1.61 million were accumulated by Vanguard Grp Inc. Credit Suisse Ag owns 200,724 shares or 0% of their US portfolio. Optimum Inv Advsr owns 20 shares for 0% of their portfolio. Buckingham Asset Management Ltd Llc stated it has 10,000 shares or 0.01% of all its holdings. Boothbay Fund Management Limited Liability Corp accumulated 15,333 shares. State Bank Of New York Mellon holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 19,352 shares. New York-based Jefferies Limited has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Susquehanna Group Llp holds 444,569 shares. Dynamic Advisor Solutions Limited Liability accumulated 10,000 shares or 0.01% of the stock.

Since April 5, 2019, it had 10 insider purchases, and 0 insider sales for $20.44 million activity. ELDRED KARY bought $12,981 worth of stock. The insider LEWIS JOEL bought $3,214. $99,851 worth of stock was bought by Uihlein Richard E on Tuesday, April 9. 18,578 shares valued at $79,514 were bought by OMENN GILBERT S on Friday, May 31. CALLICUTT JACK W bought $10,075 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Friday, May 31.

The stock of Galectin Therapeutics Inc (NASDAQ:GALT) registered an increase of 2.23% in short interest. GALT’s total short interest was 3.80 million shares in August as published by FINRA. Its up 2.23% from 3.71 million shares, reported previously. With 408,100 shares average volume, it will take short sellers 9 days to cover their GALT’s short positions. The short interest to Galectin Therapeutics Inc’s float is 11.04%.

The stock decreased 0.60% or $0.02 during the last trading session, reaching $3.33. About 445,559 shares traded or 28.71% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has declined 25.70% since August 15, 2018 and is downtrending. It has underperformed by 25.70% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $188.58 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 2 analysts covering Galectin Therapeutics (NASDAQ:GALT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galectin Therapeutics has $11 highest and $11 lowest target. $11’s average target is 230.33% above currents $3.33 stock price. Galectin Therapeutics had 4 analyst reports since February 23, 2019 according to SRatingsIntel. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by H.C. Wainwright on Thursday, March 7. FBR Capital initiated it with “Buy” rating and $11 target in Thursday, March 7 report.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Globenewswire.com which released: “Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology – GlobeNewswire” on March 22, 2019, also Investorplace.com with their article: “5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH – Investorplace.com” published on September 26, 2018, Globenewswire.com published: “Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders – GlobeNewswire” on March 06, 2019. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: Globenewswire.com and their article: “Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update – GlobeNewswire” published on May 10, 2019 as well as Nasdaq.com‘s news article titled: “Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year? – Nasdaq” with publication date: January 30, 2019.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.